Board Member
Rockwell Medical, Inc. (RMTI)Equibles does not estimate personal net worth.
Get an email with a short summary when Rockwell Medical, Inc. publishes a filing, an earnings call transcript or a press release.
Get RMTI alertsMark Strobeck is recorded as CEO and Board Member at Rockwell Medical, Inc. (RMTI). The newest filing on record that lists Mark Strobeck as CEO and Board Member at Rockwell Medical, Inc. (RMTI) is dated April 30, 2026. The proxy statement of Rockwell Medical, Inc. reports total compensation of $1,895,472 for Mark Strobeck in fiscal 2025, including a base salary of $566,500. Disclosed compensation is on record for 4 fiscal years. Mark Strobeck has spoken on 17 earnings calls across 1 company, most recently for Rockwell Medical, Inc. on August 13, 2026. Rockwell Medical, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Rockwell Medical, Inc. includes Mark Strobeck, Ph.D. (CEO and Board Member), Russell Ellison (CEO and Board Member), Russell H. Ellison, M.D., M.Sc. (CEO) and 7 others.
“Thank you for joining us today on Rockwell Medical's second quarter, 2026 earnings conference call and webcast. The second quarter was another important step forward for Rockwell Medical.”
“Thank you for joining us today for Rockwell Medical's first quarter, 2026 Earnings Conference Call and Webcast. When we set out to transform Rockwell nearly four years ago, our goal was to establish Rockwell as a financially sound, profitable, well-capitalized company that was well-positioned for future growth.”
“Thank you for joining us today on Rockwell Medical's fourth quarter and full year 2025 earnings conference call and webcast. 2025 represented a defining year for Rockwell Medical.”
“Good morning, and thank you for joining us today for Rockwell Medical's Third Quarter 2025 Earnings Conference Call and Webcast. As we approach the end of the year, I want to provide you with an update on what has truly been a year of resilience, transformation, and growth for Rockwell.”
“Good morning, and thank you for joining us today for Rockwell Medical's second quarter 2025 earnings conference call and webcast. We are past the midpoint of what we recognize as a transition year for Rockwell Medical.”
Start not stated–present
Last confirmed April 30, 2026
Start not stated–present
Last confirmed April 30, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Rockwell Medical, Inc. (RMTI) | Chief Executive Officer | $566,500 | $1,895,472 |
| 2024 | Rockwell Medical, Inc. (RMTI) | Chief Executive Officer | $566,500 | $1,310,878 |
| 2023 | Rockwell Medical, Inc. (RMTI) | Chief Executive Officer^(a)^ | $565,865 | $1,054,169 |
| 2022 | Rockwell Medical, Inc. (RMTI) | Chief Executive Officer^(a)^ | $266,539 | $711,762 |
